Research programme: trifunctional antibodies - TRION PharmaAlternative Names: Ektomun
Latest Information Update: 16 Jul 2016
At a glance
- Originator TRION Pharma
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Malignant melanoma; Small cell lung cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Malignant-melanoma in European Union (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Small-cell-lung-cancer in European Union (Parenteral)
- 05 Jul 2011 Preclinical trials in Small cell lung cancer in European Union (Parenteral)